|
Back to Home » December 2011 News » MolMed S.p.A.: Update on TK Clinical Benefit Presented at ASH and Expansion of Phase III Trial in Europe |
MolMed S.p.A.: Update on TK Clinical Benefit Presented at ASH and Expansion of Phase III Trial in Europe |
December 12, 2011
MILAN, ITALY--(Marketwire - Dec. 12, 2011) - MolMed S.p.A. (MILAN:MLM) presented at ASH an update on the clinical benefit following treatment with its investigational cell-based therapy TK for high-risk leukaemias in adult patients: patients treated, including the first patients enrolled in the ongoing Phase III trial (TK008), show restoration of a fully functional immune system. MolMed has recently started the international expansion of the trial with recruitment of the first patient in Spain. The trial expects to activate 15 centres in several different European countries, in Israel and in the United States. The primary analysis is expected in 2013.
Source URL: http://www.marketwire.com/mw/release.do?id=1597083&sourceType=3
|
|
|
|
